New
HealthMore in Health→
Phase 1 Spinal Cord Cell Therapy Trial Reports Safety Signal
Key Takeaways
- A phase 1 trial tested iPSC-derived neural progenitor cell transplantation in four patients with subacute cervical complete spinal cord injury.
- Researchers reported no tumor formation or graft-related adverse events during two to four years of follow-up.
- Median motor score improvement at 52 weeks was 13 points, with two patients improving on ASIA impairment grades.
- The study supports larger clinical evaluation but does not yet establish efficacy.
DE
DT Editorial Team··via nature.com